Feeding methods and weight evolution in newborns with congenital microcephaly due for Zika Virus

RESUMO Objetivo investigar a forma de oferta de dieta, conforme os diversos métodos de alimentação, e descrever o ganho de peso em recém-nascidos com microcefalia relacionada ao Zika Vírus, comparando-os com recém-nascidos sem microcefalia. Método estudo de coorte retrospectivo com caso controle aninhado. Informações sobre idade gestacional, peso e métodos de alimentação (seio materno, sonda nasogástrica/orogástrica, mamadeira e copo) foram coletadas em prontuários de 43 recém-nascidos com microcefalia por Zika Vírus, equiparados conforme idade gestacional com 43 recém-nascidos sem acometimentos (grupo controle), em uma maternidade de referência no Nordeste do Brasil. Os dados foram coletados desde o nascimento até a alta hospitalar. As medidas de desfecho foram pesos (ao nascer e na alta), velocidade de ganho de peso, tempo de internação e métodos de alimentação. Resultados O grupo com microcefalia apresentou menores pesos ao nascer (D=-1,67; p<0,001), inclusive com maior probabilidade de serem baixo peso (Phi=0,687; p<0,001), e no momento da alta (D=-0,87; p=0,006), do que o controle. O grupo com microcefalia também apresentou maior velocidade de ganho de peso (D=0,77; p=0,006), embora com métodos alimentares semelhantes ao grupo controle, incluindo a aceitação do seio materno, de forma exclusiva (34,9%) ou complementada (58,1%). Conclusão recém-nascidos com microcefalia relacionada ao Zika Vírus utilizaram métodos alimentares semelhantes, incluindo seio materno, aos do grupo sem acometimento. Quanto ao peso, apresentaram valores menores ao nascimento e na alta, apesar de terem um crescimento precoce pós-natal mais rápido que aqueles sem microcefalia

Family COVID-19 cluster analysis of an infant without respiratory symptoms

Diagnosing cases of coronavirus disease (COVID-19) with only non-respiratory symptoms has been challenging. We reported the diagnosis of a child who tested positive for COVID-19 with abdominal pain/diarrhea and tracked his family cluster. One member of the family tested positive for COVID-19 on real-time reverse-transcription polymerase chain reaction assay and three other family members had anti-SARS-CoV-2 antibodies. Keywords: Asymptomatic cases; Coronavirus; COVID-19; SARS-CoV-

Effects of the ethanol extract of the inner bark of Syderoxylum obtusifolium in the cyclophosphamide-induced cystitis in rats

Bezerra, Daniel Pereira “Documento produzido em parceria ou por autor vinculado à Fiocruz, mas não consta à informação no documento”.Submitted by Ana Maria Fiscina Sampaio ([email protected]) on 2017-08-28T13:32:29Z No. of bitstreams: 1 Pereira DS Effects of the ethanol extract of the inner....pdf: 537704 bytes, checksum: 4a1d6f470a0781fbef08cb691a12707d (MD5)Approved for entry into archive by Ana Maria Fiscina Sampaio ([email protected]) on 2017-08-28T13:47:44Z (GMT) No. of bitstreams: 1 Pereira DS Effects of the ethanol extract of the inner....pdf: 537704 bytes, checksum: 4a1d6f470a0781fbef08cb691a12707d (MD5)Made available in DSpace on 2017-08-28T13:47:44Z (GMT). No. of bitstreams: 1 Pereira DS Effects of the ethanol extract of the inner....pdf: 537704 bytes, checksum: 4a1d6f470a0781fbef08cb691a12707d (MD5) Previous issue date: 2013Fundação de Apoio a Pesquisa e Inovação Tecnológica (FAPITEC/SE; No 019.203.02344/2009-7) and Conselho Nacional de Pesquisa e Desenvolvimento Científico (CNPq; No 562478/2010-8)Federal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilFederal University of Sergipe. Department of Physiology. São Cristóvão, SE, BrazilIn this study, the ethanol extract of the inner bark of the Syderoxylum obtusifolium (EESob) was tested in the model of cyclophosphamide-induced hemorrhagic cystitis. Male Wistar rats were submitted to the injection of cyclophosphamide, 1 h after the treatment with EESob (200 or 400 mg/kg) or vehicle. After 24 h, the urinary bladder was excised and the edema, myeloperoxidase activity and malondialdehyde formation were measured. Also, myeloperoxidase activity and malondialdehyde formation in lung, spleen and liver and leukocyte counts in the peripheral blood were evaluated. Injection of cyclophosphamide increased myeloperoxidase activity and edema. The former was inhibited by the EESob at 400 mg/kg, but the latter was not affected. Although cyclophosphamide did not alter the bladder malondialdehyde formation, pre-treatment with EESob at both doses markedly increased this parameter. Lung and liver parameters or leukocyte counts were not altered by EESob. The spleen myeloperoxidase activity and malondialdehyde formation were not affected by cyclophosphamide, but were increased by the treatment with EESob. These results suggests that EESob administration to rats decrease myeloperoxidase activity in bladder tissue, but is accompanied by lipoperoxidation in this tissue, as well as in spleen, which do not support the use of EESob to treat cystitis

Prevalence of SARS-CoV-2 infection among urban cleaning and solid waste management workers during transmission of the Omicron variant in Brazil

This study estimated the prevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in urban cleaning and solid waste management workers during the transmission of the Omicron variant in one of the poorest regions of Brazil (the state of Sergipe). Nasopharyngeal swabs were collected from 494 workers, and the presence of SARS-CoV-2 RNA was tested by quantitative reverse-transcriptase polymerase chain reaction. Data on socio-demographic characteristics, comorbidities, vaccination status, mask use, and use of public transport to commute to the workplace were collected. The prevalence with a 95% confidence interval (CI) was calculated from the proportion of SARS-CoV-2 positive cases among the total number of individuals tested. The prevalence ratio (PR) with a 95% CI was the measure of association used to evaluate the relationship between SARS-CoV-2 infection and the exposure variables. The prevalence of SARS-CoV-2 infection was 22.5% (95% CI, 19.0 to 26.4). Individuals under the age of 40 had a higher prevalence of infection (PR, 1.53; 95% CI, 1.03 to 2.30) as well as those who did not believe in the protective effect of vaccines (PR, 1.78; 95% CI, 1.05 to 2.89). Our results indicate the need for better guidance on preventive measures against coronavirus disease 2019 among urban cleaning and solid waste management workers

Low prevalence of influenza A strains with resistance markers in Brazil during 2017–2019 seasons

This project was supported by the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior (CAPES); Programa Estratégico de Apoio à Pesquisa em Saúde (PAPES), Fundação Oswaldo Cruz, CNPq, and Coordenação Geral de Laboratórios de Saúde Pública (CGLAB) from the Brazilian Ministry of Health.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Laboratório Central de Saúde Pública de Sergipe. Aracaju, SE, Brazil.Laboratório Central de Saúde Pública de Sergipe. Aracaju, SE, Brazil.Laboratório Central do Estado do Paraná. Curitiba, PR, Brazil.Laboratório Central do Estado do Paraná. Curitiba, PR, Brazil.Secretaria de Saúde do Estado do Espírito Santo. Laboratório de Saúde Pública do Estado do Espírito Santo. Vitória, ES, Brazil / Universidade Federal do Espírito Santo. Núcleo de Doenças Infecciosas. Vitória, ES, Brazil.Secretaria de Saúde do Estado do Espírito Santo. Laboratório de Saúde Pública do Estado do Espírito Santo. Vitória, ES, Brazil / Universidade Federal do Espírito Santo. Núcleo de Doenças Infecciosas. Vitória, ES, Brazil.Laboratório Central de Saúde Pública do Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Laboratório Central de Saúde Pública do Rio de Janeiro. Rio de Janeiro, RJ, Brazil.Secretaria de Saúde do estado do Rio Grande do Sul. Laboratório Central de Saúde Pública. Porto Alegre, RS, Brazil.Secretaria de Saúde do estado do Rio Grande do Sul. Laboratório Central de Saúde Pública. Porto Alegre, RS, Brazil.Fundação Ezequiel Dias. Laboratório Central de Saúde Pública de Minas Gerais. Belo Horizonte, MG, Brazil.Fundação Ezequiel Dias. Laboratório Central de Saúde Pública de Minas Gerais. Belo Horizonte, MG, Brazil.Laboratório Central da Saúde Pública do estado da Bahia. Salvador, BA, Brazil.Laboratório Central da Saúde Pública do estado da Bahia. Salvador, BA, Brazil.Laboratório Central de Santa Catarina. Florianópolis, SC, Brazil.Laboratório Central de Santa Catarina. Florianópolis, SC, Brazil.Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos. Instituto Evandro Chagas. Ananindeua, PA. Brasil.Ministério da Saúde. Secretaria de Ciência, Tecnologia, Inovação e Insumos Estratégicos. Instituto Evandro Chagas. Ananindeua, PA. Brasil.Instituto Adolfo Lutz. Laboratório Central de Saúde Pública do Estado de São Paulo. São Paulo, SP, Brazil.Instituto Adolfo Lutz. Laboratório Central de Saúde Pública do Estado de São Paulo. São Paulo, SP, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunização e Doenças Transmissíveis. Brasília, DF, Brazil.Ministério da Saúde. Secretaria de Vigilância em Saúde. Departamento de Imunização e Doenças Transmissíveis. Brasília, DF, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.Fiocruz Fundation. Oswaldo Cruz Institute. Laboratory of Respiratory Viruses and Measles. Rio de Janeiro, RJ, Brazil.The influenza A virus (IAV) is of a major public health concern as it causes annual epidemics and has the potential to cause pandemics. At present, the neuraminidase inhibitors (NAIs) are the most widely used anti-influenza drugs, but, more recently, the drug baloxavir marboxil (BXM), a polymerase inhibitor, has also been licensed in some countries. Mutations in the viral genes that encode the antiviral targets can lead to treatment resistance. Worldwide, a low prevalence of antiviral resistant strains has been reported. Despite that, this situation can change rapidly, and resistant strain surveillance is a priority. Thus, the aim of this was to evaluate Brazilian IAVs antiviral resistance from 2017 to 2019 through the identification of viral mutations associated with reduced inhibition of the drugs and by testing the susceptibility of IAV isolates to oseltamivir (OST), the most widely used NAI drug in the country. Initially, we analyzed 282 influenza A(H1N1)pdm09 and 455 A(H3N2) genetic sequences available on GISAID. The amino acid substitution (AAS) NA:S247N was detected in one A(H1N1)pdm09 strain. We also identified NA:I222V (n = 6) and NA:N329K (n = 1) in A(H3N2) strains. In addition, we performed a molecular screening for NA:H275Y in 437 A(H1N1)pdm09 samples, by pyrosequencing, which revealed a single virus harboring this mutation. Furthermore, the determination of OST IC50 values for 222 A(H1N1)pdm09 and 83 A(H3N2) isolates revealed that all isolates presented a normal susceptibility profile to the drug. Interestingly, we detected one A(H3N2) virus presenting with PA:E119D AAS. Moreover, the majority of the IAV sequences had the M2:S31N adamantanes resistant marker. In conclusion, we show a low prevalence of Brazilian IAV strains with NAI resistance markers, in accordance with what is reported worldwide, indicating that NAIs still remain an option for the treatment of influenza infections in Brazil. However, surveillance of influenza resistance should be strengthened in the country for improving the representativeness of investigated viruses and the robustness of the analysis